However, in the clinic, imatinib resistance has become a major problem for CML treatment, mainly as a consequence of BCR-ABL mutations, BCR-ABL overexpression and other BCR-ABL-independent pathways. This evidence concerns the gene BCR and chronic myelogenous leukemia, BCR-ABL1 positive.